Brief: Kazia Presents Positive Final Data From Phase II Study Of Paxalisib In Newly Diagnosed Glioblastoma At Asco Conference
03/06/2022 12:17
June 3 (Reuters) - Kazia Therapeutics Ltd KZA.AX :
* KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF
PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE
* KAZIA THERAPEUTICS LTD- SAFETY PROFILE OF PAXALISIB WAS
HIGHLY
CONSISTENT WITH PREVIOUS CLINICAL STUDIES
Source text for Eikon: ID:nPn7k1JdNa
Further company coverage: KZA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsBrief: Kazia Therapeutics Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Kazia Announces Voluntary Delisting From ASX
Australia's Kazia Therapeutics slumps to 1-yr low on delisting announcement
Brief: Kazia Therapeutics Announces Intention To Voluntarily De-List From ASX
Brief: Kazia Therapeutics Seeks Trading Halt